Back to all bills
Standard Summary
Comprehensive overview in 1-2 paragraphs
Expands orphan drug exclusions in Medicare drug price negotiation program.
Key Points
- 1Clarifies orphan drug exclusions under Inflation Reduction Act
- 2Treats drugs for one or more rare diseases as eligible
- 3Excludes time periods when drugs had orphan designation
- 4Amends Social Security Act §1192(e)
- 5Protects incentives for rare disease drug development
Impact Areas
Pharmaceutical industryOrphan drug developersMedicare drug pricingRare disease patients
Generated by kwaipilot/kat-coder-pro:free on Nov 19, 2025